Latest Commercial Launch News

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.

Swift TV Ltd has secured a significant follow-up order from Chevron, adding 1,900 devices to its connected TV platform across key offshore accommodation sites, boosting total installations to nearly 4,000 units.

GCM Corporation has inked a binding 24-month joint development agreement with Shenzhen Wanwei Heat Conduction Technology (ALVC) to co-develop a hybrid thermal management product combining vapour chamber and VHD heat sink technologies.

FortifAI has appointed David Walker and Tim Edwards to its newly formed Advisory Board, reinforcing its push towards the commercial launch of the Nol8 AI Data Plane. These appointments bring heavyweight technology and financial services expertise to the company as it scales.

BCAL Diagnostics has developed BREASTEST Monitor, a blood test showing promising accuracy in detecting local breast cancer recurrence in women over 50, aiming to simplify post-treatment monitoring.

icetana AI has scored its first commercial wins for Antara Core, an on-premise AI surveillance platform, with prepaid contracts worth $617,000 from Millennium Services Group. The deal also debuts its floor hazard detection technology in major Australian shopping centres.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Sparc Technologies secures its first international commercial partner as Petro Vietnam Paint commits to using ecosparc® in its PERAPHENE coatings range, targeting highly corrosive environments with improved anticorrosion performance.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.